UNIGE document Scientific Article
previous document  unige:26316  next document
add to browser collection

Oral rivaroxaban for the treatment of symptomatic pulmonary embolism

Büller, Harry R
Prins, Martin H
Lensing, Anthonie W A
Decousus, Hervé
Jacobson, Barry F
Minar, Erich
Chlumsky, Jaromir
Verhamme, Peter
show hidden authors show all authors [1 - 19]
Published in New England Journal of Medicine. 2012, vol. 366, no. 14, p. 1287-97
Abstract A fixed-dose regimen of rivaroxaban, an oral factor Xa inhibitor, has been shown to be as effective as standard anticoagulant therapy for the treatment of deep-vein thrombosis, without the need for laboratory monitoring. This approach may also simplify the treatment of pulmonary embolism.
Keywords AdministrationOralAgedAnticoagulants/adverse effects/therapeutic useDrug TherapyCombinationEnoxaparin/adverse effects/therapeutic useFemaleFollow-Up StudiesHemorrhage/chemically inducedHumansInternational Normalized RatioKaplan-Meier EstimateMaleMiddle AgedMorpholines/adverse effects/therapeutic usePulmonary Embolism/drug therapy/mortalityRecurrenceThiophenes/adverse effects/therapeutic useTreatment OutcomeVitamin K/antagonists & inhibitors
PMID: 22449293
Full text
Article (Published version) (578 Kb) - public document Free access
Research groups La maladie thromboembolique veineuse (808)
Geneva Platelet Group (13)
(ISO format)
BÜLLER, Harry R et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. In: New England Journal of Medicine, 2012, vol. 366, n° 14, p. 1287-97. doi: 10.1056/NEJMoa1113572 https://archive-ouverte.unige.ch/unige:26316

3964 hits



Deposited on : 2013-02-08

Export document
Format :
Citation style :